Dr. Michael Rich

Dr. Michael Rich

Project Leader and Clinical Trial Co-Investigator
  • Partners In Health


Michael Rich, MD, MPH is a global health physician and leading expert in the field of multi-drug resistant tuberculosis (MDR-TB). 

Dr. Rich has worked with MDR-TB programs in more than fifteen countries, and is the primary author of multiple WHO guidelines on the management of drug-resistant TB (2006 and 2008), including the most recent 2015 WHO guidance on the subject of drug-resistant TB titled “Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis” (WHO/HTM/TB/2014.11).  

From 2005-2009, Dr. Rich served as the Director of PIH Rwanda, where he led a comprehensive district health-strengthening project in three districts in rural Rwanda. In 2013, Dr. Rich co-founded a non-governmental organization called PIVOT, which works in rural regions in Madagascar and provides health systems strengthening services that are modeled after PIH’s community-based activities. Dr. Rich currently serves as the Senior Medical Officer of PIVOT, where he contributes to organization’s strategic direction and leads the development of clinical and educational infrastructure. 

Dr. Rich received his MD from the University of Massachusetts, and his MPH from Harvard School of Public Health. He currently holds positions as an Associate Physician in the Division of Global Health Equity at the Brigham and Women’s Hospital, and Assistant Professor at the Harvard Medical School, Department of Global Health and Social Medicine.

Dr. Francis Varaine

Dr. Francis Varaine

Project Leader
  • Médecins Sans Frontières


Dr. Francis Varaine first started working with MSF over 30 years ago and is currently the leader of the MSF Working Group on TB and chair of the MSF Scientific Advisory Committee on DR-TB.

He participates in various international technical committees including: the WHO Strategic and Technical Advisory Group (STAG) on TB (since 2013); the expert group convened by WHO on the use of Xpert MTB/RIF assay (2013); the expert group convened by WHO on the use of bedaquiline in the treatment of MDR-TB (2013).

Varaine was a member of the GLC since its creation in 1999 to 2002 (as an alternate), and again from 2007 until its end in 2011. He has been a contributor to various guides and manuals on the programmatic management of drug resistant-TB, and has served on several guideline committees including the writing committee of the WHO guidelines for Management of Drug Resistant TB (2007, 2008 and 2011). 

Varaine has given TB-focused presentations and displayed academic posters at over 40 international conferences. Dr. Varaine holds a M.D. from Université de Grenoble.

Dr. Aamir Khan

Dr. Aamir Khan

Project Leader
  • Interactive Research and Development


Aamir Khan is an epidemiologist and social entrepreneur based in Karachi, Pakistan and Dubai, UAE. He has trained in medicine at the Aga Khan University in Karachi and has a PhD in international health from the Johns Hopkins University in Baltimore.

In 2004, Aamir founded Interactive Research and Development (IRD), a social enterprise committed to improving global health and development through process and technology innovations. IRD has global health delivery teams based in offices in Karachi, Dubai, Johannesburg, Dhaka and Jakarta supporting programs in 17 countries. IRD is a principal implementation partner to the Indus Hospital in Karachi, the Aurum Institute in Johannesburg, and the Harvard Medical School Center for Global Health Delivery–Dubai.

He is currently testing social business models for the delivery of affordable lung health and diabetes care in Bangladesh, Indonesia, and Pakistan; scaling routine immunization programs using conditional cash transfers in Pakistan, South Africa and Ethiopia; implementing TB/HIV screening and treatment programs among mining populations in South Africa; and developing sustainable models of free surgical care in Pakistan.

In addition to his own work, he has helped draft Pakistan’s successful USD 173 million Global Fund Round 9 application for scaling up MDR-TB treatment in Pakistan; and has supported its implementation in Sindh and Baluchistan provinces through the Indus Hospital TB Program. Aamir Khan is a member of the leadership team of endTB, a USD 60 million UNITAID grant to introduce new TB drugs for patients with XDR-TB and complicated MDR-TB, and of Challenge TB, a USAID-funded USD 525 million five-year cooperative agreement to accelerate the global fight against TB.

He is very excited to be an inaugural member of the Board of Directors of two leading open-source software consortiums: OpenMRS, an electronic medical records system, and OpenSRP, a smart register for frontline health workers providing integrated health care.

KJ Seung

Dr. KJ Seung

Project Leader & Observational Study Principal Investigator
  • Partners In Health


KJ Seung is a co-Leader of the endTB project and a Principal Investigator (PI) of the Observational Study. 

Dr. Seung joined PIH in 2001, after it was awarded a Gates Foundation grant to develop a scalable model for MDR-TB treatment. Dr. Seung worked closely with the Peruvian Ministry of Health to care for patients with MDR-TB, and to develop clinical protocols that eventually laid the foundation for WHO normative guidelines. 

In 2007, Dr. Seung began working in Lesotho as part of PIH's effort to combat the dual epidemics of MDR-TB and HIV, and developed the first community-based MDR-TB program in Africa. Since 2009, he has been active in North Korea, working with the Eugene Bell Foundation to introduce MDR-TB diagnosis and treatment.